Alnylam Pharmaceuticals, Inc. Q2 FY26 Results — Earnings Call Analysis

The provided transcript does not specifically mention current or future capital expenditures (capex), capital investments, or strategic investments. However, relevant clues include: - Continued investment in R&D with a 39% increase in non-GAAP R&D expenses, focusing on multiple Phase III clinical studies and early pipeline programs. - Increased SG&A expenses by 36%, driven by support for the AMVUTTRA ATTR cardiomyopathy launch and organizational scaling. - Success in launching products ex-U.S., indicating ongoing investments in international market expansion, pricing, and reimbursement activities. - Mention of exciting new collaborations aimed at driving TTR disease awareness and improving care pathways, suggestive of strategic partnerships but no explicit capex details. No explicit details on infrastructure capex or specific capital investments are provided in the call.

The transcript does not provide explicit details on current or expected orderbook or pending orders in numeric terms. However, relevant information related to demand, orders, and market dynamics includes: - Demand-driven growth was a primary factor in Q1 results, with some inventory benefits offset by pricing effects (Page 7). - Ordering patterns were affected by calendar dynamics (number of Wednesdays impacting shipments) causing a Q1 headwind (Page 7). - Sequential improvement in demand was observed from January (lowest) through February and March 2026 (Page 7). - Strong new patient market share established over 75% before the CM indication, with continued category growth (Page 11). - First-line treatment adoption is growing, with second-line use normalizing, reflecting evolving prescribing patterns (Page 6, 12). - Access expanded to nearly 90% overall and over 90% first-line access, supporting demand growth (Page 11). No specific figures on pending orders or orderbook disclosed.